Relapse Statistics 2026: Rates by Substance, Aftercare Outcomes, and What Actually Lowers the Risk

If you or someone you love is in recovery, the word "relapse" can feel terrifying. It can sound like proof that treatment did not work or that recovery is out of reach. The statistics tell a more hopeful and more honest story: relapse is common, it is predictable, and it is something you can plan for and recover from.

This guide walks through what the relapse numbers actually say, where each number comes from, when relapse is most likely, and what genuinely lowers the risk. The goal is not to scare you with percentages but to help you use them.

Key numbers at a glance

Every figure below links to its primary source, with the year the data were published or collected noted inline.

• 40 to 60 percent of people treated for a substance use disorder experience relapse, comparable to relapse rates of 50 to 70 percent for hypertension and asthma (National Institute on Drug Abuse; the underlying research dates to the 1990s and early 2000s, compiled in McLellan et al., JAMA, 2000).
• Studies show relapse rates of approximately 50 percent within the first 12 weeks after completing intensive inpatient treatment (StatPearls, NCBI Bookshelf, updated 2023).
• In a 16-year alcohol study, 62.4 percent of people who got help achieved remission by year three, versus 43.4 percent of those who did not (Moos and Moos, Addiction, 2006).
• In that same cohort, only 42.9 percent of helped remitters relapsed over 16 years, versus 60.5 percent of those who remitted without help (Moos and Moos, 2006).
• After residential opioid detoxification alone, 91 percent of patients returned to use, 59 percent within one week; entering aftercare significantly delayed relapse (Smyth et al., Irish Medical Journal, 2010).
• 61 percent of people treated for methamphetamine use relapsed within the first year after discharge; ongoing self-help or treatment participation cut the relapse hazard by 71 percent (Brecht and Herbeck, Drug and Alcohol Dependence, 2014).
• Only 3 to 5 percent of smokers who quit without help remain abstinent at 6 to 12 months (Hughes et al., Addiction, 2004).
• 74.3 percent of U.S. adults who ever had a substance use problem, about 23.5 million people, considered themselves in recovery or recovered in 2024 (SAMHSA, 2024 National Survey on Drug Use and Health, published 2025).
• Intensive outpatient programs produce outcomes comparable to inpatient care for most people, a conclusion rated at a high level of evidence (McCarty et al., Psychiatric Services, 2014).
• Drug overdose deaths in New Hampshire fell from 484 in the 12 months ending December 2022 to a provisional 268 in the 12 months ending December 2025; Massachusetts fell from 2,647 to a provisional 1,336 over the same period (CDC provisional data, accessed July 2026).

What is relapse in addiction recovery?

A relapse is a return to substance use after a period of abstinence or reduced use. Addiction medicine treats substance use disorder as a chronic, relapsing condition of the brain, which is why a return to use is understood the same way doctors understand a flare-up in asthma or a rise in blood pressure: as a sign that the treatment plan needs adjusting, not as a personal failure.

The National Institute on Drug Abuse is explicit about this. As with many other chronic illnesses, a return to drug use after a period of abstinence is often part of the treatment and recovery process rather than the end of it.

Is a slip the same as a relapse?

People often separate a brief "slip" or "lapse," a single instance of use, from a full relapse, a sustained return to old patterns. The distinction matters because catching a slip early, before it becomes a full return to use, is one of the most powerful things a person and their care team can do.

What do relapse statistics actually say?

The most widely cited figure comes from NIDA: roughly 40 to 60 percent of people treated for a substance use disorder experience relapse. On its own that number can sound discouraging. In context, it is reassuring.

NIDA places that rate side by side with two other chronic, manageable illnesses in its science of addiction overview:

• Substance use disorder: about 40 to 60 percent relapse
• High blood pressure (hypertension): about 50 to 70 percent
• Asthma: about 50 to 70 percent

In other words, the relapse rate for addiction is no higher, and is often lower, than for conditions we routinely treat as ongoing medical issues. Nobody calls a blood pressure spike a failure of character. The same logic applies here.

How old is the 40 to 60 percent figure?

Here is something most pages that quote this statistic never mention: it is not a fresh annual number. The comparison traces to a landmark review by McLellan and colleagues published in JAMA in 2000, which compiled treatment outcome studies from the 1980s and 1990s to argue that drug dependence should be managed like other chronic medical illnesses. NIDA continues to cite the range because the underlying insight has held up, but readers deserve to know its vintage. Throughout this page, every statistic is labeled with the year its data were published or collected so you can judge each number for yourself.

The honest bottom line: the range is a durable, decades-old benchmark, not a prediction about any individual, and it says nothing about what happens when care continues after treatment, which is where the newer data get encouraging.

"I tell patients that a relapse rate of this size is medically ordinary. We do not treat a return to use as starting over from zero, any more than we would restart all of medicine after an asthma flare. We look at what changed, adjust the plan, and keep going. Patients who understand that usually get back on track faster."

Dr. Richard Marasa, Medical Director, Clear Steps Recovery

Does relapse mean treatment did not work?

No. A relapse means the current plan needs to change, whether that is the level of care, the medication, the therapy approach, or the support structure around a person. Treatment that includes a clear path back after a setback is treatment that is working as designed. This is exactly why aftercare is built into a complete recovery plan rather than treated as optional.

Relapse rates by substance

Relapse risk is not one number. It varies by substance, by whether a person received structured treatment, and by how long they have been in recovery. The table below includes only findings from peer-reviewed studies, each labeled with its follow-up window and publication year.

Two patterns stand out across every substance. First, relapse concentrates early, in the first days, weeks, and months. Second, in every study that measured it, structured help after the initial treatment episode substantially improved the odds. The opioid figure describes detoxification alone, without ongoing treatment, which is why modern guidelines treat detox as a starting point to be followed by continuing care, never as a complete treatment.

The recovery counterweight: most people get better

Relapse statistics only describe one side of recovery. The other side almost never appears on statistics pages: most people who ever develop a substance use problem eventually recover.

According to the 2024 National Survey on Drug Use and Health, published by SAMHSA in 2025, 31.7 million U.S. adults, 12.2 percent of all adults, said they had ever had a problem with their use of drugs or alcohol. Of those, 74.3 percent, about 23.5 million people, considered themselves to be in recovery or to have recovered. Among adults aged 26 or older, that recovery figure reaches 75.0 percent.

Hold those two numbers together: 40 to 60 percent of people relapse at some point, and roughly three quarters of people who ever had a problem describe themselves as recovered or recovering. Both are true, because relapse and recovery are not opposites. For millions, relapse was a chapter in a recovery story that succeeded.

When is relapse most likely to happen?

Relapse risk is not spread evenly across recovery. It is highest in the early period after treatment, when new coping skills are still fragile and old triggers are still close.

Clinical reviews of relapse note that many studies show relapse rates of approximately 50 percent within the first 12 weeks after completing an intensive inpatient program, according to the StatPearls relapse prevention overview on the NCBI Bookshelf (last updated 2023). The substance-specific data agree: in the 2010 opioid study, most lapses happened within a week of discharge, and in the 2004 smoking review, most relapse occurred within the first 8 days of a quit attempt.

The encouraging flip side: the longer someone sustains recovery, the more their risk tends to fall. In the methamphetamine cohort, 61 percent of relapses happened in year one, but only 14 percent across the following four years combined. Time in recovery, paired with continued support, is protective.

What does relapse look like before it happens?

One of the most useful findings for prevention is that relapse is rarely a sudden event. According to a widely cited Yale Journal of Biology and Medicine review (Melemis, 2015), relapse is a gradual process that often begins weeks or months before any substance touches a person's lips. It tends to move through three stages:

1. Emotional relapse. The person is not thinking about using, but self-care slips: poor sleep, skipped meetings, bottling up emotions, isolating.
2. Mental relapse. Cravings appear, and an internal tug-of-war starts: part of the mind wants to use, part wants to stay in recovery.
3. Physical relapse. The person actually returns to use.

Because the warning signs show up early, learning to recognize emotional and mental relapse gives people a real window to intervene. That is the core idea behind relapse prevention planning, and it is why relapse can happen even when things seem to be going well.

What are common relapse triggers?

Risk factors and triggers vary from person to person, but research and clinical experience consistently point to a familiar set:

• Negative emotional states such as depression, anxiety, anger, or loneliness
• The "HALT" states: being Hungry, Angry, Lonely, or Tired
• Untreated co-occurring mental health conditions
• Weak or absent support systems
• Poor coping skills and low confidence in one's ability to stay sober
• Exposure to high-risk people, places, and situations
• Cravings without a plan for how to ride them out

A 2019 systematic review of 321 studies in Psychiatry Research confirmed this picture for alcohol: psychiatric comorbidity, disorder severity, craving, and use of other substances were consistently associated with relapse, while supportive social networks, self-efficacy, and a sense of purpose were protective.

Aftercare and continuing care: the outcome data

This is the section most relapse statistics pages skip entirely, and it holds the most actionable numbers here: what happens when care continues after the initial treatment episode.

Abstinence with versus without formal help

The clearest long-term evidence comes from the 16-year study by Moos and Moos published in Addiction in 2006, which followed 461 people with alcohol use disorders. Two findings define the field:

• Remission: 62.4 percent of people who obtained help (treatment or Alcoholics Anonymous) achieved remission by the 3-year mark, versus 43.4 percent of people who did not.
• Durability: among those who achieved 3-year remission, only 42.9 percent of the helped group relapsed over the following 16 years, versus 60.5 percent of the group that had remitted without help.

Put simply, help nearly reversed the long-term odds: remission reached with support held up for a majority, while remission reached alone broke down for a majority.

What kind of continuing care works best

A comprehensive 2021 review in Alcohol Research: Current Reviews (McKay) synthesized decades of continuing care trials, including a meta-analysis of 19 randomized controlled trials. Its conclusions:

• Continuing care produced significantly better substance use outcomes overall, with effects that were modest on average but grew stronger at longer follow-up.
• Interventions with longer planned duration (at least 12 months) and more active efforts to engage and retain patients produced benefits more consistently.
• In four of six rigorous trials, adding active outreach, such as clinician-initiated check-ins, significantly improved drinking outcomes.
• Higher-risk patients benefited most: people with continued use during initial treatment, weaker social support, or lower motivation gained the most from extended continuing care.

The substance-specific studies echo this. In the methamphetamine cohort, participating in self-help or additional treatment after discharge was associated with a 71 percent lower relapse hazard (hazard ratio 0.29, published 2014). In the opioid study, failing to enter aftercare was one of the strongest predictors of early relapse (2010).

"The first ninety days after intensive treatment are where I see outcomes diverge. Two people can leave the same program in the same shape, and the one with scheduled follow-ups, a written plan, and someone checking in does noticeably better over time. A relapse prevention plan works because it moves decisions out of the moment of craving and into a calmer moment when the person could think clearly."

Dr. Richard Marasa, Medical Director, Clear Steps Recovery

Structured aftercare typically includes ongoing counseling, peer support and 12-step access, regular check-ins, and a written relapse prevention plan that names each person's triggers, warning signs, and concrete steps to take when cravings hit.

Inpatient versus outpatient: what the outcome data show

Families often assume residential treatment is categorically stronger than outpatient care. The published evidence does not support that assumption for most patients.

A systematic review by McCarty and colleagues in Psychiatric Services (2014) assessed intensive outpatient programs (IOPs) across 13 studies published between 1995 and 2012, including randomized controlled trials, and assigned the finding a high level of evidence: IOPs are as effective as inpatient or residential treatment for most individuals seeking care. Across studies, 50 to 70 percent of participants reported abstinence at follow-up, and where trials compared settings directly, differences tended to converge within months.

The right way to read this is not that one setting is better than the other. It is that level of care should match clinical need. People with unstable housing, severe co-occurring conditions, or a need for medically managed withdrawal may genuinely require residential care or a medical detox referral first. For many others, an intensive outpatient program delivers equivalent outcomes while they keep living at home, working, and practicing recovery skills in the environment where they will use them. Our guide to inpatient versus outpatient rehab walks through how clinicians make that match.

"Outpatient care asks people to practice recovery in real life while they are still in structured treatment, and for the right patient that is exactly the point. The skills get tested on a Tuesday evening at home, not in a facility, with the care team still beside them. Some patients truly need a higher level of care first, and part of our job is being honest about which situation is which."

Dr. Richard Marasa, Medical Director, Clear Steps Recovery

Veteran relapse and recovery data

Veterans carry distinct relapse risk factors: higher rates of post-traumatic stress, chronic pain, and the transition out of military structure. Nationally representative veteran-specific relapse rates are scarce; here is what the primary sources do show.

• Pooled 2022 to 2024 national survey data show about 1 in 4 veterans who served in a combat zone reported past-month binge drinking, and about 1 in 8 had a past-year alcohol use disorder, both significantly higher than among veterans who did not serve in one. Past-year substance use disorder overall stood at 17.5 percent among combat-zone veterans versus 15.4 percent among other veterans, a difference the survey did not find statistically significant (SAMHSA NSDUH veterans spotlight, published 2025).
• More than 1 in 10 veterans have been diagnosed with a substance use disorder, slightly higher than the general population, and 65 percent of veterans entering treatment report alcohol as their most frequently misused substance (NIDA, Substance Use and Military Life, 2019).
• In a 5-year follow-up of 207 veterans discharged from a VA residential substance use program (Decker et al., Military Medicine, 2017), the factors associated with higher relapse were co-occurring psychiatric conditions and failure to complete the program, and veterans who completed treatment attended significantly more aftercare. The VA's research office maintains an active portfolio on veteran substance use treatment outcomes.

The practical takeaway matches the civilian data: completion and aftercare are where the leverage is. Veterans in New Hampshire and Massachusetts can access outpatient treatment through VA Community Care rehab programs, and our overview of veterans' addiction treatment through VA Community Care explains how referrals and eligibility work.

Dual diagnosis and relapse risk

Co-occurring mental health conditions are one of the most consistently documented relapse risk factors in the entire literature.

• In 2024, 21.2 million U.S. adults had both a mental illness and a substance use disorder in the past year (SAMHSA, 2024 NSDUH, published 2025). Among those who received any care, most received treatment for only one of the two conditions.
• The 2019 systematic review in Psychiatry Research found psychiatric comorbidity, particularly depression and anxiety, consistently and significantly associated with relapse to alcohol use.
• A dedicated review of relapse among people with co-occurring disorders in Clinical Psychology Review (Bradizza et al., 2006) examined relapse predictors across mood, anxiety, schizophrenia-spectrum, and personality disorders, with the stated goal of improving treatment for people who live with both conditions at once.
• In the veteran cohort above (2017), comorbid psychiatric conditions were among the strongest predictors of relapse after residential treatment.

This is why integrated care that treats mental health conditions alongside substance use is not an add-on but a core relapse prevention strategy. Treating half of a dual diagnosis leaves the other half pulling toward relapse.

New Hampshire and Massachusetts: the local numbers

National statistics can feel abstract. Here is the recent trend in the two states Clear Steps Recovery serves, compiled from the CDC's provisional overdose surveillance. Figures count drug overdose deaths of all intents for 12-month periods ending in December.

Source: CDC National Center for Health Statistics, Vital Statistics Rapid Release, Provisional Drug Overdose Death Counts, accessed July 2026. Recent counts are provisional and may be updated as records are finalized. State-level detail is published in the New Hampshire Drug Monitoring Initiative reports (NH DHHS) and the Massachusetts DPH Current Opioid Statistics series.

Both states have seen a dramatic turn: from the 12 months ending December 2022 to the same period ending December 2025, provisional overdose deaths fell about 45 percent in New Hampshire and about 50 percent in Massachusetts. For families, the local implication of everything above is simple: the period right after treatment is the highest-risk window, and both states have continuing care resources, from state-funded supports to outpatient providers like our Londonderry, New Hampshire and Needham, Massachusetts programs, that exist to cover it.

What lowers the risk of relapse?

The same statistics that show how common relapse is also show how much it can be reduced. Evidence-based care does not promise a relapse-free recovery, but it meaningfully shifts the odds and shortens any return to use when it does happen.

Behavioral therapy

Therapies like cognitive behavioral therapy help people identify the thoughts and patterns that lead toward use and replace them with healthier coping strategies. CBT is especially valuable because it also treats the depression and anxiety that so often drive relapse.

Medication-assisted treatment

For opioid and alcohol use disorders in particular, medication-assisted treatment combines FDA-approved medications with counseling. As both NIDA and SAMHSA describe, medications such as buprenorphine, methadone, naltrexone, and acamprosate reduce cravings and withdrawal, which directly lowers relapse risk and helps people stay engaged in care. Given the 91 percent post-detox relapse figure above, medication support is a first-line consideration for opioid recovery, not a last resort.

Treating co-occurring conditions

Because untreated mental health conditions are a major relapse driver in study after study, integrated dual diagnosis care is one of the most effective ways to protect long-term recovery.

Structured aftercare and a written relapse prevention plan

Since the early post-treatment months carry the highest risk, the support that follows a program is decisive: the 16-year data show helped remission holds while unhelped remission usually breaks. Practical, day-to-day strategies matter here too; our guide to tips for staying sober covers the habits that support a plan between appointments.

What should you do if relapse happens?

Treat a relapse as medical information, not a verdict. The most important move is to act fast: reach out to your treatment team or an admissions line so the plan can be adjusted before a slip becomes a longer return to use. People who respond quickly after a setback are far more likely to get back on track. A relapse can become a turning point when it prompts a stronger, better-matched plan.

If you have relapsed and feel discouraged, that feeling is normal and it is not the whole story. Our drug addiction treatment and aftercare teams help people start again every day, with no judgment. In a crisis, call or text 988 for the Suicide and Crisis Lifeline.

The bottom line on relapse statistics

The numbers are clear and, read correctly, encouraging. Relapse affects 40 to 60 percent of people in recovery at some point, no more than for other chronic illnesses we manage well. It is most likely early, it usually announces itself through warning signs, and it responds to good care: remission achieved with help lasts for a majority, continuing care measurably improves outcomes, and three quarters of American adults who ever had a substance use problem now consider themselves recovered or in recovery. Knowing the statistics is not a reason to expect failure. It is a reason to plan, to build support, and to treat any setback as a step in the process rather than the end of it.

If you are worried about relapse, recovering from one, or supporting someone who is, our admissions team is here, confidentially and without judgment, across New Hampshire and Massachusetts.

Methodology and sourcing notes

Every statistic on this page comes from a primary source: federal agencies (NIDA, SAMHSA, CDC, VA), state health departments, peer-reviewed journals, or the NCBI Bookshelf. No figure was sourced from treatment industry blogs or aggregator sites. Each number is labeled with the year its data were published or collected, including the 40 to 60 percent headline figure, whose underlying research dates to the 1990s and early 2000s. Survey figures reflect the 2024 National Survey on Drug Use and Health, published in July 2025. CDC overdose counts are provisional 12-month totals accessed in July 2026 and may be revised. Every citation was verified live before publication. This page was medically reviewed by Dr. Richard Marasa and last reviewed on July 3, 2026.